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Abstract:
Background:
There is  an urgent  need for  new therapies  to treat  cancer  metastasis.  Fish oil,  with high omega 3 fatty acid content,  has shown
anticancer activity and signal transduction inhibitors have shown anti-metastatic properties.
Objective:
To provide preliminary in vitro data on the anti-migration potential of signal transduction inhibitors and co-administered fish oil.
Methods:
MCF-7, TamR and FasR breast cancer cell lines were used to determine the effects of combinations of PD98059, LY294002 and fish
oil in growth assays. Modulations of p-Src and COX-2, both mediators of motility and invasion, were then determined by Western
blotting and IHC to ascertain effects on migration potential.
Results:
Migration rates  for  the three cell  lines  examined were ranked:  FasR>TamR>MCF-7 (p  <0.05).  Addition of  fish oil  reduced the
number  of  TamR cells  migrating  after  48h  (p  <0.05),  while  the  addition  of  PD98059  and  LY294002  also  decreased  migratory
potential of TamR cells (p <0.05). Addition of PD98059 and LY294002 to TamR cells did not result in a significant decrease in p-
Src levels; as  was  the  case  when  PD98059,  LY294002  and  4-hydroxytamoxifen  were  added  to  MCF-7  cells.  However,  the
 co-administration of fish oil markedly reduced p-Src and COX-2 expression in both cell lines.
Conclusion:
Co-administration of a commercial fish oil with signal transduction inhibitors results in decreased cell migration via an unknown co-
operative mechanism and could constitute a novel approach for the treatment of breast cancer metastasis.
Keywords: Cancer, Cell migration, Signal transduction inhibitor, PD98059, LY294002, Fish oil.
1. INTRODUCTION
Under normal conditions, the constituent cells of most tissues remain resident within the particular tissue and do not
spread to  other  tissues  and locations  within  the  body.  Metastasis,  the  most  deadly  aspect  of  cancer,  is  a  multi-step
process  by  which  cancer  cells  spread  throughout  the  body,  and  involves  many  growth  factors,  their  receptors  and
angiogenic factors [1, 2]. This ability of cells to migrate is the fundamental difference between benign and malignant
tumors, with only the malignant variant possessing this capability. Malignant tumors contain both neoplastic cells and
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non-neoplastic cellular components, which include macrophages, lymphocytes, fibroblasts and endothelial cells [3]. The
cellular elements of the tumor are surrounded by an Extracellular Matrix (ECM) and are interactions between these are
fundamental in tumorogenesis [4].
Breast cancer is associated with a high incidence of metastasizing, usually via the lymphatic system, giving a much
poorer  patient  prognosis  [5].  Lymph  node  metastasis  is  the  most  common site  of  secondary  colonization  of  breast
cancer cells, with the likely hood of metastatic spread increasing with increasing tumor grade and in hormone receptor
negative cancers. Metastasis from the point of origin seems to be the organ of origin specific. It has been established for
over a decade that breast cancer cells preferentially metastasize to bone and lung [6]. Tamoxifen is the gold standard
treatment for hormone-sensitive, Estrogen Receptor positive (ER+) breast cancer, although intrinsic resistance affects
30% of patients who do not respond to tamoxifen treatment. Acquired resistance is also thought to affect many initially
responding patients, which is believed to lead to the development of a more aggressive phenotype; hence our focus on a
tamoxifen-resistant cell line.
Marine oils, such as fish oil, typically have a high content of omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) which possess anti-inflammatory activity in the COX-2 mediated inflammation pathway
[7], and anticancer properties [8]. It has previously been shown that a combination of PD98059 (a highly selective in
vitro inhibitor of MEK1 activation and the MAP kinase cascade) and LY294002 (a highly selective inhibitor of PI3k)
and fish oil can suppress the growth of both MCF-7 and TamR cells [9, 10]. The EGFR is known to be relevant in
driving resistance as it is increased in response to endocrine agents in the endocrine-sensitive stage and maintained into
the resistant context where it helps to drive proliferation in the presence of endocrine agent [11, 12]. The MAPK and
PI3K pathways have already been implicated in metastasis [13, 14] and so PD98059 and LY294002 are already known
to have anti-metastatic properties, and here we wanted to examine whether co-administration of fish oil might modulate
and  enhance  such  effects.  Insights  into  the  mechanisms  involved  in  metastasis  of  breast  cancer  have  discerned  a
possible role for COX-2 in both tumorogenesis and metastatic spread of breast cancer. An increasing body of evidence
supports  a  role  for  COX-2  in  many  malignancies,  including  those  of  the  colon,  prostate  and  breast  [15].  A  study
investigating the relationship between COX-2 and various clinical markers involved in breast cancer tumorogenesis
revealed that upregulation of COX-2 significantly correlated with distant metastasis [16].
This  study  tested  the  hypothesis  that  a  novel  combination  therapy  involving  fish  oil  and  signal  transduction
inhibitors  demonstrates  anti-migratory  properties  for  cancer  cell  lines  in  vitro.  The  hypothesis  was  tested  using
commercial  fish oil,  with  high omega-3 polyunsaturated fatty  acid content,  administered to  breast  cancer  cell  lines
simultaneously with the signal transduction inhibitors PD98059 and LY294002.
2. METHODOLOGY
2.1. Materials
PD98059  and  LY294002  were  purchased  from  Promega,  Southampton,  UK.  Fish  oil  capsules  (Seven  Seas
Maximum Strength: 63% Omega-3 of which 51% EPA and 21.4% DHA) were purchased from a local store. Hanks
balanced buffered salt solution (HBBSS), HEPEs, gentamycin sulphate, sodium bicarbonate PBS, PBS + 0.02% Tween,
sodium citrate, citric acid, methyl green, copper sulphate, paraffin wax pellets, 30% hydrogen peroxide solution, sodium
hydroxide, hydrogen chloride, DPX mountant, 1,8-cineole, 4-hydroxytamoxifen and were all obtained from Sigma-
Aldrich Company Ltd, Poole, UK. Phospho-MAPK primary antibody, phospho-Akt and COX-2 primary antibodies
were from Cell Signalling Technology, New England Biolab (Hitchin, UK). HRP labelled anti-rabbit polymer, normal
goat serum, DAB chromagen plus substrate, Ki-67 primary antibody and delimiting pen were from Dako, Ely, UK.
Solvents (HPLC grade), Whatman filter papers (45), Whatman parafilm were all from Fisher Scientific (Loughborough,
UK). Rabbit polyclonal anti-Src (total and phospho), RPMI (1640) cell culture medium and Foetal Calf Serum (FCS)
were from Invitrogen Life Technologies (Paisley, UK). Tissue culture plasticware was from Nalge Nunc International
(Roskilde, Denmark). Parental MCF-7 cells were a gift from AstraZeneca, Macclesfield, UK. TamR and FasR cell lines
were produced and characterised in-house, based generally on a method reported in the literature [17].
2.2. Growth Assays
Growth  assays  were  performed  as  reported  previously  [9].  Briefly,  the  growth  rates  of  three  cell  lines  were
compared as follows: MCF-7, TamR and FasR cells were grown to 70% confluency, passaged and seeded into 24 well
plates  at  a  density  of  1.5  million  cells  per  plate.  Cells  in  each  well  were  trypsinised  and  counted  using  a  Coulter
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Multisizer II on days 1, 4, 7 and 9. The test substances PD98050, LY294002, fish oil and 4-hydroxytamoxifen (MCF-7
cells only) are detailed in Table 1. To determine the effects of the on cell growth, cells were again seeded into 24-well
plates and left overnight to attach. After 24 h equilibration, base counts were taken and then cells were treated with the
appropriate  agents  with  cell  counts  being  taken  on  days  1,  2,  4,  7  and  9  as  above;  cell  growth  data  is  presented
graphically following normalisation to control. Cells were re-treated on day 4.
Table 1. The treatments used in growth assays to detect the effects of formulation constituents on the growth rate of both
MCF-7 cells and TamR cells. Cells were seeded at a density of 1.5 million cells per plate on day 0. On day 1 cells were counted
and then treated. Additional counts were at days 4, 7 and 9 and treatments replenished on day 4.
Cell Line Treatments Concentrations
MCF-7 DMSO 0.1µL mL-1
4-hydroxytamoxifen 1 x 10-7 M
PD98059 25 µM
LY294002 5 µM
LY294002 + PD98059 + 4-hydroxytamoxifen As in single treatments
Fish oil 1 µL mL-1
Fish oil + LY294002 + PD98059 + 4-hydroxytamoxifen As in single treatments
E2 1 x 10-9 M
TamR DMSO 0.1 µL mL-1
PD98059 25 µM
LY294002 5 µM
LY294002 + PD98059 As in single treatments
Fish oil 1 µL mL-1
Fish oil + LY294002 + PD98059 As in single treatments
E2 1 x 10-9 M
Faslodex 1 x 10-7 M
2.3. Cell Migration Assay
Initially,  migration assays were carried out  to compare the migratory potential  of  three breast  cancer cell  lines:
MCF-7, TamR and FasR. Secondly, we studied the effects of fish oil and fish oil plus PD98059 and LY294002 on the
migration of TamR cells. Cell migration assays were performed using a modified Boyden chamber assay [4]. Briefly,
the  underside  surface  of  Transwell® inserts  having an 8μm pore  size  (Corning)  was  coated with  fibronectin  (from
human plasma: 1 mg mL-1 in 0.05 M TBS pH 7.5) in PBS (1:1000) to mimic the normal composition of the extracellular
matrix. MCF-7, TamR and FasR cells (80-90% confluency) were passaged using the protocol outlined previously. Fresh
culture media (600 μL) was applied to the underside of the coated inserts. Passaged cells were seeded onto the upper
surface  of  the  insert  at  a  density  of  80,000  cells  per  well.  These  were  then  incubated  at  37  ºC  in  a  humidified
atmosphere of 5% CO2 in air for 2 days. After this time, media was removed from the insert and non-migratory cells
were  removed  from  the  upper  surface  of  the  insert  using  a  fresh  cotton  bud.  Migratory  cells  were  fixed  in  3.7%
formaldehyde (in PBS) for 15 min, washed in PBS for 5 min and stained with crystal violet (0.5% w/v). Cell migration
was then quantitated by counting the number of cells per field of view (7 random fields chosen per membrane) using an
Olympus BH-2 phase microscope integrated with an Olympus DP-12 digital camera system (Olympus, Oxford, UK).
This procedure was then repeated using TamR cells in the presence of 1 µL mL-l fish oil +/- 25 µM PD98059 and 5 µM
LY294002. In this instance the wells of the modified plate were filled with wRPMI (SFCS, fungicide and antibacterial)
with  either  0.1  µL  mL-1  DMSO  (control),  1  µL  mL-1  fish  oil  or  1  µL  mL-1  fish  oil,  25  µM  PD98059  and  5  µM
LY294002.
2.4. Western Blot Analysis for c-Src and p-Src and COX-2
After reaching 70% confluency, the cultured cells were incubated for 3h with compounds as detailed in Table 2.
After which, cells were washed with ice-cold PBS for 5 min and subsequently lysed by addition of 150 μL of ice-cold
lysis buffer (50 mM tris, pH 7.5, 5 mM EGTA, 150 mM NaCl and 1% Triton X100) containing protease inhibitors (2
mM sodium orthovanadate, 20 mM sodium fluoride, 1 mM phenylmethylsulphonyl fluoride, 20 lM phenylarsine, 10
mM sodium molybdate, 10 l g mL-1 leupeptin and 8 l g mL-1 aprotinin). Lysates were then centrifuged at 13000 rpm for
10 min at 4 °C, after which, the supernatant was aliquoted into fresh Eppendorf microcentrifuge tubes and stored at -20
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°C. Protein was then quantified using the DC protein assay kit (BioRad, Hemel Hempstead, UK). Equal amounts of
protein were separated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked
in 5% milk and incubated with primary antibodies. Proteins were detected using HRP-tagged secondary antibodies and
chemiluminescence  (Pierce  and  Warriner  Ltd.  Chester,  UK).  Blots  were  exposed  to  X-ray  film  and  protein  was
quantified using image densitometry (BioRad, Hemel Hempstead, UK) and normalised to β-actin as an internal control
for equal protein loading.
Table  2.  Treatments  for  MCF-7 and TamR cells  prior  to  Western blot  and immunocytochemical  analysis.  PD98059 and
LY294002 were made up in DMSO, while 4-hydroxytamoxifen was made up in ethanol. Treatments were incubated for 3
hours, after which protein was extracted for western blot assays and cells were fixed for ICC assays. Cells were maintained at
37°C with 5% CO2.
Cell line Treatment
MCF-7 0.1 µL mL-1 DMSO (Control)
1µL mL-1 Fish oil
1 x 10-7 M 4OHTam, 25µM PD98059, 5µM LY294002
1 µL mL-1 Fish oil, 1 x 10-7 M 4OHTam, 25µM PD98059, 5µM LY294002
TamR 0.1 µL mL-1 DMSO (Control)
1 µL mL20-1 Fish oil
25µM PD98059, 5µM LY294002
1 µL mL-1 Fish oil, 25µM PD98059, 5µM LY294002
2.5. Immunocytochemical Detection of Total and Activated c-Src and COX-2 in MCF-7 and TamR Cells
Prior to culture, sterile glass coverslips were placed into 60 mm sterile plastic dishes. MCF-7 and Tam-R cells, at
log phase growth, were passaged and seeded onto the coverslips at a density of 5 x 105 cells per dish. Cells were grown
as a monolayer and upon reaching 60-70% confluency were treated, as described in Table 2, for 3h. The cells were then
fixed in formal saline (4.5g NaCl, 550 mL water, 50 mL 37% formaldehyde) and stored in sucrose storage media (0.33
g NaCl, 42.8 g sucrose, 250 mL PBS, 250 mL glycerol) at -20°C. The coverslips bearing the fixed cells were removed
from storage at -20ºC and washed in PBS until residual sucrose storage media was washed away. The coverslips were
subsequently washed twice in PBS-TWEEN for 5 min. After adequate washing, primary antibody was applied. Protein
was detected using HRP labeled secondary antibody and DAB chromagen. Coverslips were then counterstained with a
10% methyl green solution. The coverslips were then observed and images captured using an Olympus BH-2 phase
microscope integrated with an Olympus DP-12 digital camera system (Olympus, Oxford, UK).
2.6. Statistical Analysis
Statistical analyses, one-way ANOVA and post-tests, were carried out using Minitab for Windows; significance was
defined at p <0.05.
3. RESULTS
3.1. Growth Assays
Fig. (1) shows the growth rate of untreated MCF-7, TamR and FasR cells over 9 days. It is clear that with hormone
resistance,  growth  rate  accelerates,  as  shown  with  TamR  and  FasR  cells  compared  to  the  parental  and  hormone-
sensitive MCF-7 cells. FasR cells showed a significantly elevated growth rate compared to both TamR and MCF-7 cells
(p  0.012 and 0.05 respectively). TamR cells apparently showed accelerated growth rates compared to MCF-7 cells;
however, this was not statistically significant (p >0.05). The effect of the active constituents of the formulation on the
growth of both MCF-7 and TamR cells were then examined.
The MCF-7 cells, shown in Fig. (2), displayed typical hormone-sensitive behaviour. Treatment with estradiol gave
an  elevated  growth  rate,  whilst  4-hydroxytamoxifen  (1  x  10-7  M)  gave  a  reduction  in  cell  growth  to  68.9  ±  13.1%
compared to control growth. The addition of 25 µM PD98059, 5 µM LY292002 and 1 µL mL-1 fish oil, separately,
reduced MCF-7 growth to 81.5 ± 11.4, 66.2 ± 14.5 and 81.7 ± 13.7% of control MCF-7 growth respectively (p 0.001).
A  major  synergistic  effect  was  observed  when  the  cells  were  dosed  with  the  combination:  1  x  10-7  M  4-
hydroxytamoxifen,  25  µM PD98059  and  5  µM LY292002,  where  cell  growth  was  reduced  by  97% (p  0.001);  no
significant reduction was observed by the inclusion of 1 µL mL-1 fish oil in the dose.
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Fig. (1). Growth curves showing the growth rates of MCF-7, TamR and FasR cells. Cells were seeded at a density of 1.5 million cells
per plate on day 0. Cells were counted on days 1, 4, 7 and 9 and media was replenished on day 4. Cells were incubated at 37°C with
5% CO2. Cell counts represent the mean number per 3 counts (n=3 ± SD). FasR cells showed a significantly elevated growth rate
compared to both TamR and MCF-7 cells (p 0.012 and 0.05 respectively). Passage numbers were 12, 14, 20 for MCF-7 cells; 22, 25,
30 for TamR cells; 31, 35 and 40 for FasR cells.
Fig. (2). Growth curves showing the growth rates of MCF-7 cells when treated with 4- hydroxytamoxifen, PD98059, LY294002 and
fish oil (both singly and in combination); and also estradiol. Cells were seeded at a density of 1.5 million cells per plate on day 0.
Cells were counted on days 1, 2, 4, 7 and 9 and media and treatments were replenished on day 4. Cells were incubated at 37°C with
5% CO2.  Cell  counts  represent  the mean number per  3 counts  (n=3 ± SD).  Passage numbers were 19,  21,  24.  All  test  solutions
significantly different to control (p 0.001).
Fig. (3) shows growth assays performed on the tamoxifen-resistant cell line, TamR. The absence of an estradiol-
induced  elevation  in  growth  rate  highlights  the  loss  of  hormone  sensitivity.  Although  the  TamR  cells  displayed
 
 
 






	




      	 
  




	




















	
      	 
  




	
















 !
Co-Administration Of Fish Oil With Signal Transduction The Open Biochemistry Journal, 2018, Volume 12   135
insensitivity to estradiol, they were still sensitive to the true anti-estrogen Faslodex/Fulvestrant (Fas). Incubation with 1
x 10-7 M Faslodex reduced growth to 58.4 ± 8.3% of control TamR growth suggesting that the cells were still sensitive
to the anti-estrogen challenge. The addition of 5µM LY292002 reduced TamR growth to a similar degree, as seen with
Faslodex: 58.3 ± 9.3% of control growth. Incubation with 25 µM PD98059 or 1 µL mL-1 of fish oil inhibited the growth
of  TamR cells  to  similar  levels:  68.1  ±  8.1  and  64.9  ±  7.4% of  control  TamR growth  respectively  (p  0.001).  The
combination PD98059 and LY292002 had a major effect by reducing growth to 1.5 ± 0.2% of control, the addition of
fish oil produced no further observable reduction.
Fig. (3). Growth curves showing the growth rates of TamR cells when treated with PD98059, LY294002 and fish oil (both singly and
in combination) and also Faslodex and estradiol. Cells were seeded at a density of 1.5 million cells per plate on day 0. Cells were
counted on days 1, 2, 4, 7 and 9 and media and treatments were replenished on day 4. Cells were incubated at 37°C with 5% CO2.
Cell counts represent the mean number per 3 counts (n=3 ± SD). Passage numbers were 25, 27 and 32. All test solutions significantly
different to control (p 0.001).
3.2. Cell Migration Assays
The migratory potential of three in-house cell lines was first assessed. Fig. (4) shows the number of MCF-7, TamR
and FasR cells  migrating after  48 h.  It  was clear  that  TamR cells  migrated significantly more than MCF-7 cells  (p
0.004) and that FasR cells migrated significantly more than both MCF-7 and TamR cells (p 0.001 and 0.001). One-way
ANOVA determined that there was a highly significant difference in the migratory potential of these three cell lines (p
<0.001). Although FasR cells displayed the greatest migratory potential, TamR cells have been used as a model for
tamoxifen resistance, therefore this cell line was chosen to investigate the anti-migratory potential of fish oil and the
two signal transduction inhibitors
Fig.  (5)  shows  the  effect  of  the  fish  oil  used,  alone  and  in  combination  with  PD98059  and  LY294002,  on  the
migration of TamR cells. One-way ANOVA analysis revealed that the migratory potential of control, fish oil treated
and fish oil plus STIs are significantly different (p 0.001). Fish oil gave a significant reduction in the number of TamR
cells migrating after 48h (p <0.05), while the addition of the two signal transduction inhibitors potentiated this decrease
significantly compared to both control cells (p >0.001) and fish oil treated cells (p 0.003).
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Fig. (4). Migration assay showing the differences in the number of MCF-7, TamR and FasR cells migrating after 48h. Cells were
seeded onto fibronectin-coated porous membranes at a density of 80,000 cells per well, incubated and allowed to migrate for 48h at
37°C with 5% CO2. No of cells migrated represents the mean number of cells per field of view (7 fields per insert were counted) (n=3
± SD). Passage numbers were 12, 14, 20 for MCF-7 cells, 22, 25, 30 for TamR cells and 31, 35 and 40 for FasR cells.
Fig. (5). Migration assay demonstrating the significant reduction in the number of TamR cells migrating after 48h, when incubated
with  control,  1µL mL-1  fish  oil;  and the  significant  potentiation of  this  effect  when the  cells  were  dosed with  1  μM L-1  fish  oil
simultaneously with 25 µM PD98059 and 5 µM LY294002. Cells were seeded at a density of 80,000 cells per well and incubated at
37 °C with 5% CO2 No of cells migrated represents the mean number of cells per field of view (7 fields per insert were counted) (n=3
± SD). Passage numbers were 23, 27 and 30.
3.3. Western blot Analysis of Total and Activated c-Src and Total COX-2
COX-2 is an intermediate response gene that encodes a 71 KDa protein that is induced in response to inflammation
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[18]. Western blot analysis of total COX-2 levels in MCF-7 and TamR cells showed that TamR cells had an elevated
level of total COX-2, as displayed in Fig. (6). Fish oil, incubated for 3h, reduced total COX-2 protein levels in both cell
types.  The  addition  of  PD98059  and  LY294002  to  TamR  cells  and  the  addition  of  the  two  STIs  and  4-
hydroxytamoxifen to MCF-7 cells also reduced the amount of total COX-2, albeit, to a lesser extent than fish oil. The
addition of fish oil to the two treatments mentioned previously allowed a further additive reduction of the total COX-2
protein in both MCF-7 and TamR cells.
Fig. (6). Western blot analysis of the levels of total COX-2. MCF-7 and TamR cells were incubated with FO (1 μM L-1 fish oil), PD
(25 µM PD98059), LY (5 µM LY294002) and 1 x 10-7 M 4-hydroxytamoxifen (MCF-7 cell only) for 3h. Cells were lysed and
protein  extracted  and  quantified  for  equal  loading.  Protein  was  separated  by  SDS-PAGE.  Proteins  were  immobilised  on  a
nitrocellulose  membrane and immunoprobed using a  total  COX-2 primary antibody.  B.  Densitometric  analysis  of  total  COX-2.
Densitometry was performed using Alpha Digi Doc TM RT camera and image analysis system, Genetic Research Instrumentation,
Essex, UK. M7- MCF-7 cells, TR- TamR cells (n=3 ± SD). Passage numbers were 23, 27 and 30.
The protein expression of total Src and phospho-Src (p-Src) was also investigated in both cell lines when incubated
with constituents of the transcutaneous formulation,  as shown in Fig.  (7)  Western blot  analysis of total  Src protein
revealed that this protein was elevated in TamR cells compared to MCF-7 cells. Although the addition of PD98059 and
LY294002 to TamR cells  or  the addition of  PD98059,  LY294002 and 4-hydroxytamoxifen to MCF-7 cells  did not
result in a significant decrease in p-Src levels, the addition of fish oil reduced p-Src expression markedly in both cells.
The incubation of fish oil, PD98059 plus LY294002 reduced expression of p-Src in TamR cells to a similar degree as
the fish oil alone. Also the combination of fish oil, PD98059, LY294002 and 4-hydroxytamoxifen showed no additional
reduction in p-Src expression compared to incubation of MCF-7 cells with fish oil alone. Western blot of β-actin, shown
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in Fig. (8), confirmed equal protein loading due to the equal band width detected in each lane.
Fig.  (7).  A. Western Blot  for  the levels  of  total  Src,  and phosphorylated Src (at  tyr  416)  protein.  MCF-7 and TamR cells  were
incubated with FO (1 μmL-1 fish oil), PD (25 µM PD98059), LY (5 µM LY294002) and 1 x 10-7 M 4-hydroxytamoxifen (MCF-7
cells only) for 3h. Cells were lysed and protein extracted and quantified for equal loading. Protein was separated by SDS-PAGE.
Proteins were immobilised on a nitrocellulose membrane and immunoprobed using a cell signalling technology total Src or phospho-
Src primary antibody. B. Densitometric analysis of total Src, and phosphorylated Src (at tyr 416) protein. M7- MCF-7 cells, TR-
TamR  cells.  Densitometry  was  performed  using  Alpha  Digi  Doc  TM  RT  camera  and  image  analysis  system,  Genetic  Research
Instrumentation, Essex, UK. Passage numbers were 23, 27 and 30.
Fig. (8). Western Blot for the levels of β-actin. MCF-7 and TamR cells were incubated with DMSO (0.1μml-1), FO (1μml-1 fish oil),
PD (25µM PD98059), LY (5µM LY294002) and 1 x 10-7 M 4-hydroxytamoxifen (MCF-7 cells only) for 3h. Cells were lysed and
protein  extracted  and  quantified  for  equal  loading.  Proteins  were  separated  by  SDS-PAGE,  immobilised  on  a  nitrocellulose
membrane and immunoprobed using β-actin primary antibody.
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3.4. Immunocytochemical (IHC) detection of p-Src and total COX-2 in MCF-7 and TamR cells
To verify the results seen in the Western blot analysis of p-Src and total COX-2, IHC detection of these proteins was
carried out on both cell lines. Fig. (9A-H) shows the results for the detection of total COX-2 in MCF-7 and TamR cells.
Staining in both cell lines was granular and localised to the cytoplasm, similar to previous IHC analysis for COX-2
[19]. Figs. (9A and B) shows that small amounts of total COX-2 were present in MCF-7 cells without treatment (under
basal conditions). Total COX-2 protein was lower in MCF-7 cells Figs. (9A-9B) compared to TamR cells, as shown in
Figs. (9I-9J). Incubation for 3h with fish oil reduced the levels of COX-2 protein in both MCF-7 cells Figs. (9C-9D)
and TamR cells Figs. (9K-9L). Incubation with 1x 10–7 M 4-hydroxytamoxifen, 25 µM PD98059 and 5 µM LY294002
also reduced total COX-2 levels in MCF-7 cells, shown in Figs. (9E-9F). The addition of fish oil to this combination
treatment seemed to completely eradicate the total COX-2 protein signal, shown in Figs. (9G-9H).
Fig. (9 A-H). ICC detection of total COX-2 in MCF-7 cells incubated with 0.1 µL mL-1 DMSO (A & B), 1 µL mL-1 fish oil (C & D),
1  x  10-7  M  4-hydroxytamoxifen,  25  µM  PD98059  and  5  µM  LY294002  (E  &  F)  or  1  µL  mL-1  fish  oil,  1  x  10-7  M  4-
hydroxytamoxifen, 25 µM PD98059 and 5 µM LY294002 (G & H) for 3h. Cells were grown to 70% confluency on TESPA coated
glass coverslips and fixed using formal saline. Primary antibody was NEB total COX-2 rabbit primary at 1/40 for 1.5h. Secondary
antibody was DAKO Rabbit EnVision peroxidase labeled polymer antibody for 1.5h. Magnification: A, C, E, G x 10 and B, D, F, H
x 40. Passage numbers were 22, 27 and 33.
Figs.  (9  M-N)  shows  TamR  cells  incubated  with  the  combination  of  25  µM  PD98059  and  5  µM  LY294002
demonstrating that although this treatment does knock-down total COX-2 protein expression after 3h, it is not as great
as the knockdown observed with the incubation of 1 µL mL-1 fish oil. The addition of fish oil to the two STIs produced
downregulation of total COX-2 similar to that seen with fish oil alone.
Both cell lines were also analysed for p-Src levels, as displayed in Fig. (10 A-H). This data shows cytoplasmic
localization of p-Src in both cell lines although at high levels of magnification some p-Src appeared localised to the
nucleus. Staining intensity for cytoplasmic p-Src was much greater in TamR cells than MCF7 cells (compare Fig. 10A)
with 10I). Addition of fish oil (1 µL mL-1) for 3h gave a dramatic reduction in p-Src protein staining in MCF-7 cells
Figs. (9 C-9 D) and in TAMR cells Figs. (10 K-10 L). Incubation of MCF-7 cells with 1 x 10–7 M 4-hydroxytamoxifen,
25 µM PD98059 and 5 µM LY294002 also reduced the intensity of p-Src staining; however, this was a much more
subtle decrease in p-Src than that seen when cells were incubated with fish oil. A similar pattern was observed with the
incubation  of  TamR  cells  with  25  µM  PD98059  and  5  µM  LY294002  Figs.  (9I-9J).  A  moderate  reduction  was
observed, which was not as profound as the knockdown seen with the addition of fish oil.
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Fig. (9 I-P). Immunocytochemical detection of total COX-2 in TAMR cells. Cells were incubated with 0.1 µL mL-1 DMSO (I & J), 1
µL mL-1  fish  oil  (K  & L),  25  µM PD98059 and 5  µM LY294002 (M  & N)  or  1  µL mL-1  fish  oil,  25  µM PD98059 and 5  µM
LY294002 (O & P) for 3h. Cells were grown to 70% confluency on TESPA coated glass coverslips and fixed using formal saline.
Primary antibody was NEB total COX-2 rabbit primary antibody at 1/40 for 1.5h. Secondary antibody was DAKO Rabbit EnVision
peroxidase labeled polymer antibody for 1.5h. Magnification: I, K, M, O x 10, L x 20 and J, N, P x 40, scale bar = 50 μm. Passage
numbers were 15, 19 and 30.
Upon incubation of MCF-7 cells with the combination of 4-hydroxytamoxifen, PD98059, LY294002 and fish oil
Fig. (10 G-H), p-Src protein levels were reduced to levels similar to those seen with incubation with fish oil alone Figs.
(10 C-10 D.  10 O-10 P)  shows that incubation of TamR cells with 1 µL mL-1  fish oil,  25 µM PD98059 and 5 µM
LY294002 gave the greatest knockdown in p-Src protein expression in this cell line.
4. DISCUSSION
An early event in tumorogenesis is the loss of cell-to-cell adhesion within the primary tumor. This event leads to the
development of an elevated invasive phenotype and subsequent migration of cancer cells into the ECM and local tissues
[20]. This work aimed to determine the combined effects of fish oil and two STIs on the migratory potential of cultured
human breast  cancer  cells,  in  vitro.  Three  cell  lines  were  chosen to  represent  invasive  (TamR and FasR)  and non-
invasive (MCF-7) phenotypes.
Initially, the growth rates of the three cell lines were examined. The hormone-resistant cell lines (TamR and FasR)
showed  accelerated  growth  rates  compared  to  the  parental  MCF-7  cell  line,  with  the  order  in  growth  rate  being
MCF-7<TamR<FasR. The elevation in growth rates seen in both tamoxifen and Faslodex resistance has been previously
demonstrated and it is accepted that growth factor signalling is responsible for this trend. It was reported that TamR
cells displayed enhanced growth rates along with an augmented invasive capacity [21]. The increased growth rate seen
with TamR cells was observed previously, correlating to similar growth seen with E2-induced proliferation in MCF-7
cells.
Growth curves examined previously [9] were repeated to confirm that the cells displayed the same phenotype and
behaved in the same way when challenged with fish oil, PD98059, LY294002 and 4-hydroxytamoxifen. Figs. (1 and 3)
showed that both MCF-7 and TamR cells behaved very similarly when incubated with these compounds. Interestingly,
no significant differences in growth rates between control and treated MCF-7 and TamR cells were observed after 2
days, suggesting that the results of 2-day migration assays were a consequence of altered migratory potential of the cells
rather than an effect on cell number.
Investigations into the migratory potential of the three cell lines followed the same pattern as growth rates, as shown
in Fig. (4), where the order of metastatic potential was MCF-7<TamR<FasR. This observation of a correlation existing
between loss of hormone sensitivity, elevated growth rate and elevated invasive behaviour has been reported previously
[22,  23]  with  the  switch  to  growth  factor  signalling  suggested  as  being  responsible  for  this  phenomenon.  EGFR
signalling  is  involved  in  a  wide  array  of  processes  in  tumor  biology  and  tumorogenesis,  including  invasion  and
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metastasis [24]. Indeed, several studies using cells engineered to over-express certain growth factors and their ligands
have  uncovered  that  growth  factor  signalling  is  sufficient  to  induce  migration  and  invasion  [25,  26].  The  elevated
migratory potential of the cells is thought to arise from an altered cell-to-cell and cell-to-matrix adhesion [21].
The  involvement  of  COX-2  in  tumorogenesis  was  first  brought  to  light  with  the  discovery  that  regular  Non-
Steroidal Anti-Inflammatory Drug (NSAID) usage inversely correlated with colon cancer risk. Since then, elevated
COX-2 expression has been correlated to higher tumor grade and metastatic potential of many solid cancers such as
colon, lung, prostate and breast [15]. In breast cancer, as with other cancers, the exact role of COX-2 in tumorogenisis
remains to be elucidated, although reports suggest a role for it  in many processes involved in metastasis,  including
invasion, chemotaxis and angiogenesis as well as proliferation [27].
The findings in the current work indicate that total COX-2 protein is expressed in both hormone-sensitive MCF-7
and tamoxifen-resistant TamR breast cancer cells, albeit at much lower levels in MCF-7 cells, as shown in both the
western blot and ICC experiments. In breast cancer cell lines COX-2 expression has only been demonstrated previously
in  hormone  insensitive  cells  with  an  increased  invasive  capacity,  such  as  MDA-MB-231  cells  [28].  Expression  of
COX-2 has previously been shown in MCF-7 cells, although this expression was only seen post tetradecanoyl phorbol
acetate induction [29].  Results  in the current  work show constitutive basal  COX-2 expression in MCF-7 cells.  The
expression of COX-2 in TamR cells has been previously demonstrated in-house, which correlates with its expression in
other highly motile cells such as MDA-MB-231 [29].
Over-expression of COX-2 has been linked to an increase in invasive and metastatic potential both in vitro and in
vivo. Elevated COX-2 has been shown to enhance the levels of expression and secretion of vascular endothelial growth
factor-C  (VEGF-C),  a  potent  mediator  of  lymphangiogenesis.  It  was  further  revealed  that  knockdown  of  VEGF-C
expression reduced the migration of the highly migratory cell line MDA-MB-231 [30]. Silencing of COX-2 in MDA-
MB-231 was found to show a reduction in oncogenic markers such as MMP-1, interleukin 11 and chemokine receptor 4
[31].  The COX-2 knockdown also induced up-regulation of  anti-metastatic  markers  such as  thrombospondin-1 and
Epstein-Barr-Induced  3.  These  cells  also  showed  a  decreased  migratory  and  invasive  capacity.  Overexpression  of
COX-2, and so overproduction of PGE2, can also promote migration via crosstalk with the EGFR. PGE2 can induce
shedding of active EGFR ligands from the plasma membrane, thus activating EGFR signalling pathways [20]. PGE2 can
also transactivate EGFR through Src stimulation [32].
Fig. (10 A-H). Immunocytochemical detection of phospho-Src in MCF-7 cells. Cells were incubated with 0.1 µL ml-1 DMSO (A &
B), 1 µL ml-1 fish oil (C & D), 1 x 10-7 M 4-hydroxytamoxifen, 25 µM PD98059 and 5 µM LY294002 (E & F) or 1 µL mL-1 fish oil,
1 x 10-7 M 4-hydroxytamoxifen, 25 µM PD98059 and 5 µM LY294002 (G & H) for 3h. Cell were grown to 70% confluency on
TESPA coated glass coverslips and fixed using formal saline. Primary antibody was Cell Signal Technology phoshpo-Src rabbit
primary antibody at 1/40 for 2h. Secondary antibody was DAKO Rabbit  EnVision peroxidase labeled polymer antibody for 2h.
Magnification: A, C, E, G x 10 and B, D, F, H x 40, scale bar = 50μm. Passage numbers were 22, 27 and 33.
Addition of PD98059 and LY294002 resulted in a slight reduction of COX-2 expression in both MCF-7 and TamR
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cells. A study described how PD98059, previously thought to be a specific inhibitor of the p42/44 MAPK signalling
pathway, inhibited the conversion of Arachidonic Acid (AA) into Thromboxane (Tx) A2 [33]. The authors showed that
PD98059 was capable of preventing platelet aggregation induced by collagen and AA but not by thrombin. Further
experiments revealed that this was a result of inhibition of COX-1 and COX-2 and not the inhibition of thromboxane
synthase. This inhibition of COX by PD98059 may have been the reason for the additive knockdown in COX-2 protein
in the Western blot analysis of total COX-2 protein seen when TamR cells were simultaneously incubated with both
fish oil and PD98059 plus LY294002 for 2h.
The migration assay displayed in Fig. (5) revealed that incubation with 1 µL mL-1 of fish oil reduced the migratory
potential of TamR cells significantly. Dietary fat has been the topic of much debate in its effect on tumorigenesis and
much work has concentrated on the type of fat intake and the different effects they have on both prostanoid/eicosanoid
synthesis and on tumor growth, proliferation and apoptosis, however, their involvement in metastasis remains largely
unknown and unexplored.
Omega-3 polyunsaturated fatty acids Eicosapentaenoic Acid (EPA) and docosahexaenoic acid (DHA), which are
contained in high concentrations in the fish oil used, are capable of inhibiting cell growth in the highly invasive MDA-
MB-231 breast cancer cell line [34], which correlated with results obtained in the current work Figs. (2 and 3). The use
of selective COX or LOX inhibitors revealed that the inhibition of cell growth was as a result of LOX inhibition and
reduction in leukotriene production rather than as a result of reduced prostaglandin production. Subsequent studies by
the same group then explored the role of COX and LOX in metastasis of MDA-MB-231 cells in a nude mice model.
This  study showed that  the growth of  the tumors  was lessened when the rats  were fed with a  diet  rich in  omega-6
polyunsaturated fatty acids. EPA and DHA, however, the tumors of mice fed on a diet high in n-6 PUFAs displayed
increased growth rates. The occurrence and severity of lung metastasis in mice fed a diet rich in omega-3 PUFAs were
significantly  less  than control  or  mice  fed  a  diet  rich  in  n-6  FAs.  The authors  also  correlated  this  with  the  type  of
prostanoids  produced  in  the  tumor  cells.  The  mice  fed  a  diet  rich  in  omega-3  FAs  showed  high  levels  of  series  3
prostaglandins and leukotrienes while mice fed a diet high in omega-6 FAs showed no series 3 PGs or LKs but showed
high levels of AA metabolites such as PGE2 [35].
The  generally  accepted  mechanism  for  the  chemopreventative  actions  of  omega-3  PUFAs,  such  as  EPA is  the
suppression of AA-derived prostanoids, in particular, PGE2 [36]. PGE2 is known to have a role in tumor progression
through effects on proliferation and apoptosis. However, the role of this prostanoid in cell migration and metastasis is
still unknown. It has been observed that PGE2 can reverse the antiangiogenic effects of NSAIDs in CRC cells [37].
Omega-3 PUFAs compete with AA for the cyclooxygenase enzyme and instead of forming series 2 prostanoids, which
are highly inflammatory, series 3 prostanoids are produced. Series 3 prostanoids display a far weaker inflammatory
action compared to series 2 prostanoid, which is believed to be the mechanism by which omega-3 PUFAs give rise to
anti-inflammatory actions. The biological role of PGE3,  derived from omega-3 PUFAs has received scant attention.
Human cells lack the ability to convert n-6 PUFAs into omega-3 PUFAs due to the lack of the fat-1 gene. A549 cells
were transfected with the Caenorhabditis elegans fat-1 gene that encodes for an omega-3 desaturase that converts n-6
PUFAs to omega-3 PUFAs [38] and results showed that transfection efficiency was 90% and resulted in a rapid and
remarkable  modification  of  the  omega-6/omega-3  ratio  of  fatty  acids  in  the  cell  without  the  need  for  dietary
intervention. In fact, a reversal in the ratio was seen whereby omega-3 levels were twice as high as n-6 levels. The same
group later used this model to explore the role of high omega-3 PUFA concentrations on the metastatic potential of
A549  cells.  This  subsequent  study  again  showed  90%  transfection  efficiency  and  highlighted  several  interesting
observations. The authors showed that fat-1 gene expression led to an inhibition of adhesion and invasive potential of
A549 cells,  along  with  an  elevation  in  apoptosis.  They  also  used  determined  that  MMP-1,  ITG-α2 and  NM23-H4,
which are all involved in the metastatic process, were downregulated in the transfected A549 cells [38].
The fatty acid receptor CD36 has recently been implicated as important for metastasis-initiating cells, and [39] it
was found that the presence of CD36+ metastasis-initiating cells correlated with a poor prognosis for numerous types of
carcinomas, and that inhibition of CD36 impaired metastasis. However, their work was based upon palmitic acid - a
saturated long chain fatty acid. The administration of EPA and DHA, the major PUFAs within the fish oil, was found to
reduce migration, invasion and macrophage chemotaxis in prostate cancer cell lines [40] and supports the findings in
the current paper.
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Fig. (10 I-P). Immunocytochemical detection of phospho-Src in TamR cells. Cells were incubated with 0.1 µL mL-1 DMSO (I & J),
1  µL mL-1  fish oil  (K  & L),  25 µM PD98059 and 5 µM LY294002 (M  & N)  or  1  µL mL-1  fish oil,  25µM PD98059 and 5µM
LY294002 (O & P) for 3h. Cell were grown to 70% confluency on TESPA coated glass coverslips and fixed using formal saline.
Primary antibody was Cell Signal Technology phospho-Src rabbit primary antibody at 1/40 for 2h. Secondary antibody was DAKO
Rabbit EnVision peroxidase labeled polymer antibody for 2h. Magnification: I, K, M, x 10, O x 20 and J, L, N, P x 40. Passage
numbers were 15, 19 and 30.
The addition of the two signal transduction inhibitors also inhibited the migration of TamR cells. Dissection of Src
signalling  in  migration and invasion of  hormone-resistant  cell  lines  has  exposed a  role  in  this  process  for  both  the
MAPK/ERK1/2 pathway and the PI3K pathway. The acquisition of endocrine resistance is paralleled with an elevation
in the activity of Src kinase. Activated Src kinase has the ability to interact with many molecules such as growth factor
receptors,  steroid  receptors,  integrins  and  cell-cell  adhesion  receptors  and  thus  is  involved  in  many  tumorogenic
processes such as proliferation, differentiation, migration and invasion [41]. Inhibition of Src kinase activity is known to
decrease  the  motility  and  invasion  of  TamR  cells  by  reducing  the  levels  of  activated  FAK  and  paxillin  and  by
elongating focal adhesions. Interestingly, concomitant incubation with the EGFR inhibitor Gefitinib augmented this
decrease in motility and invasion suggesting a role for the EGFR signalling pathway and downstream mediators [21].
The  MAPK  (or  ERK  1/2)  signalling  pathway  has  been  correlated  to  and  proved  to  be  necessary  for  the  invasive
capability  of  Dunning  rat  prostatic  adenocarcinoma  cell  lines,  furthermore,  the  addition  of  PD98059  significantly
reduced the invasive capability of such cell lines. However, PD98059 inhibited cell motility independent of any effects
on adherence to the ECM or the secretion of ECM degrading proteases such as MMP2 [42]. A subsequent study found
contradictory results regarding MMP2 [43] in which the role of ERK 1/2 was confirmed in breast cancer metastasis to
the brain; however, blockade of this pathway with PD98059 suppressed the secretion of MMP2, which they suggest was
the main mechanism by which ERK 1/2 increased metastatic potential due to MMP2 being a pivotal candidate in cell
motility.  TGF-β  is  a  potent  mediator  of  the  immune  response,  inflammation,  tumor  growth  and  metastasis.  Three
mitogen-activated  protein  kinase  signalling  pathways  (Jun,  ERK1/2  and  p38  MAPK  contribute  to  TGF-β  induced
increased tumor migration and invasion. The constitutive activation of TGF-β type 1 receptor was found to give rise to
the elevated migratory potential of MDA-MB-231 cells and that this could be reversed by blockade of MAPK signalling
[13].
PGE2 has been shown to change the morphology of colorectal cancer cells by inducing reorganisation of actin stress
fibres  and focal  adhesion complexes,  through the binding of  PGE2  to  the EP4 receptor.  This  binding activated Akt
through an EGFR/Src-mediated mechanism was reversed by the addition of LY294002 [32]. This data supports a role
for PI3K/Akt in migration. The overexpression of COX-2 in TamR cells in this study would give rise to elevated levels
of PGE2 and thus elevated activation of Akt. This could explain the inhibition in migration of TamR cells, seen in this
study when incubated with PD98059 and LY294002 Fig. (3). The overexpression of Akt2 has also been linked to an
increased β integrin expression, which in turn led to increased invasion and metastasis of human breast and ovarian
cancer cells [44]. This suggests that the blockade of Akt with LY294002 would reverse this event. The Rho family of
proteins belongs to the Rho-GTPases, which are responsible for the assembly of the contractile actomyosin machinery
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that is imperative for most types of cell motility. Overexpression of the Akt1 protein has been shown to phosphorylate
and target the tumor suppressor TSC2 (tuberous sclerosis 2) for degradation. This led to reduced Rho-GTPase activity,
which in turn led to decreased actin stress fibres, focal adhesions and cell motility and invasion [45].
MAPK signalling is also involved in migration and invasion. TGF-β is a potent mediator of the immune response,
inflammation, tumor growth and metastasis. Three mitogen-activated protein kinase signalling pathways (Jun, ERK1/2
and p38 MAPK) contribute to TGF-β induced increased tumor migration and invasion. The constitutive activation of
TGF-β type 1 receptor was found to give rise to the elevated migratory potential of MDA-MB-231 cells and that this
could  be  reversed  by  blockade  of  MAPK  signalling  [13].  It  has  recently  been  discovered  that  MAPK  signalling
contributes to metastasis of renal cell carcinoma. ERK 1/2 is overexpressed in this malignancy and blockade of MAPK
signalling reduced cell proliferation by the disruption of tumor vasculature [46]. The addition of fish oil reduced levels
of activated Src in both cell lines. Although the mechanism for this is not clear, it may represent an indirect effect of the
anti-inflammatory polyunsaturated fatty acids (PUFA) within fish oil [47] via downregulation of COX-2 hence PGE2 - a
known stimulator of Src. Since PGE2-stimulation of Src can promote EGFR-mediated cell motility [48], these data may
explain the reduction in TamR cell migration following fish oil treatment. Interestingly, given the observations that high
levels of activated Src are associated with loss of endocrine response [49], the ability of fish oil to suppress Src activity
may suggest a further advantage of using such an agent for transcutaneous delivery of endocrine agents.
The  proposed  3-component  system  comprised  of  fish  oil  and  signal  transduction  inhibitors  is  particularly
appropriate for an implant or localized delivery, where the oil itself forms at least part of the base for the other actives.
Intravenous delivery is likely to result in the metabolism of PUFAs and wide systemic distribution; however, our earlier
work has established the efficacious anti-cancer activity of these agents via transcutaneous delivery [9, 10], where the
formulation was applied to the skin surface in vitro. Furthermore, we previously showed that localized passive delivery
via the mammary papilla is a plausible non-invasive means of delivering anti-cancer drugs directly to the breast [50] to
treat breast cancer.
CONCLUSION
This  study  has  demonstrated  that  when  challenged  simultaneously  with  PD98059,  LY292002  and  fish  oil,  the
mediators of cell  motility and invasion p-Src and COX-2 are inhibited in breast  cancer cell  lines,  and migration of
TamR cells is also reduced significantly. The cooperative mechanism of PD98059, LY292002 and fish oil remains to be
elucidated. Although the fish oil used contains relatively high levels of EPA and DHA, the effect of each of these in
purified form also needs to be established. However, the results overall support the hypothesis that the simultaneous
administration of signal transduction inhibitors and a commercial fish oil has anti-migratory properties in tamoxifen-
resistant  and  invasive  cells  via  a  novel  multi-pronged  mechanism,  and  may  have  a  role  as  a  novel  anti-metastatic
therapeutic system.
LIST OF ABBREVIATIONS
AA = Arachidonic Acid
COX-2 = Cyclooxygenase-2
DHA = Docosahexaenoic acid
EGFR = Epidermal Growth Factor Receptor
EPA = Eicosahexaenoic acid
ECM = Extracellular matrix
HBBSS = Hanks Balanced Buffered Salt Solution
HPLC = High Performance Liquid Chromatography
MAPK = Mitogen-Activated Protein Kinase
NSAID = Non Steroidal Anti-Inflammatory Drug
PGE2 = Prostaglandin E2
PI3K = Phosphoinositide 3-kinase
PUFA = Polyunsaturated fatty acid
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